

MICHAEL ANTHONY EVANS, RPH, FASHP

27 Pine Road | Stillwater, PA 17878 | (570) 854-2803 | maevans2803@gmail.com

PROFILE

An innovative results-oriented health care leader with demonstrated ability to lead transformational health care delivery services by successful integration and partnering of multidisciplinary health system resources focusing on a compassionate, high quality, patient centric care philosophy.

- Strategic planning and execution
- Innovative thinking
- Resource restructuring and optimization
- Pharmacy practice transformation
- Implementation of system best practice care models
- Vendor relations/Collaborations
- Integration of research into clinical practice
- Population health management
- Evidence based/Data driven thinking

PROFESSIONAL CAREER

ASSOCIATE PROFESSOR, GEISINGER COMMONWEALTH SCHOOL OF MEDICINE
May 2019-Present | Scranton, Pa

CHIEF PHARMACY OFFICER / VICE PRESIDENT, ENTERPRISE PHARMACY
April 2018-Present | Geisinger, Danville Pa

Responsibilities

- Administrative pharmacy oversight throughout Geisinger health system
- Overall strategy development
- Leadership of the pharmacy pillars:
 - Acute and Ambulatory Clinical Pharmacy Programs
 - Retail/Mail Order/Specialty Pharmacies
 - Geisinger Health Plan Managed Care Pharmacy
 - Infusion/VITALine
 - System Formulary/Procurement
 - Data/Informatics
 - Center for Pharmacy Innovation and Outcomes
 - Knowledge Management
 - Operations and Compliance

Notable Achievements

- Culture: Developed and implemented a large restructure for all Geisinger pharmacy entities in a horizontally aligned process focused on the patient no matter where they are in the continuum of care
- Collaboration/Partnerships: Originated and continually promoting a systematic process to bring all Geisinger pharmacy and the health system providers together working in our “OneGeisinger” collaborative approach providing patients with quality care at a lower cost.
- Quality/Service: Continuing to build CarePaths for disease states where unwarranted variation of poor clinical outcomes and fiscal financial risk to both patient and organization exist. New CarePaths being developed are for Atopic Dermatitis, Wet Macular Degeneration, Migraine, and Osteoporosis.
- Financial Sustainability: Led an aggressive operational and financial improvement for Geisinger system by integrating contracts and distribution agreements with savings of more than \$90 million dollars for the system.

ASSOCIATE VICE PRESIDENT, CLINICAL STRATEGY AND INNOVATION
November 2015-March 2018 | Geisinger, Danville Pa

Responsibilities

- Lead and direct clinical pharmacy program strategy development
- Oversee Acute and Ambulatory Clinical Pharmacy Programs along with the PGY1 Residency Program and PGY2 Oncology Residency Program
- Grow and support new and expanding clinical programs
- Develop business plans for total cost of care pharmacy programs
- Ensure system business goals are achieved and objectives are aligned with the organization's broader mission, vision, and driving strategies
- Lead internal efforts to align care support services activities with care delivery processes through collaborative transformation efforts with clinical departments
- Translate pharmacy transformation projects into improvements in care delivery processes that impact clinical outcomes
- Assume lead role in analyzing, identifying and tracking pharmacy opportunities
- Promote the impact of pharmacy in care delivery through the development and oversight of a robust research program including publications and presentations
- Lead the process of prioritizing projects for funding while providing input on project selection and future direction
- Lead clinical use evaluation initiatives for business, clinical or quality opportunities.

Notable Achievements

- Culture: Developed and encouraged an environment for all Geisinger stakeholders to become transparent to facilitate a horizontal or a “One Geisinger” approach to patient care
- Collaboration/Partnerships: Initiated a systematic process to bring all Geisinger pharmacy resources together for a patient centric model; examples include ProvenCare® Hepatitis C and ProvenCare® Diabetes
- Quality/Service:
 - Identified, planned and developed pharmacy’s role in disease specific models of care where unwarranted variation of poor clinical outcomes and fiscal financial risk to both patient and organization existed
 - Showing continued growth in the Medication Therapy Disease Management (MTDM) program to over 60 FTE Pharmacist seeing over 35,000 patients/month
- Financial Sustainability: Developed a disease specific total cost of care dashboard to determine system viability; example includes in FY16, ProvenCare® Psoriasis showed that using ultraviolet light instead of a “biologic” had a cost avoidance of \$5M

CO-DIRECTOR OF CENTER FOR PHARMACY INNOVATION AND OUTCOMES
November 2015-March 2018 | Geisinger, Danville Pa

Responsibilities

- Lead a professional team of researchers to conduct transformative research to help optimize medication use
- Facilitate the connection between clinical/operations of pharmacy practice with research to become a living learning healthcare system
- Serve as principal or co-investigator on funded and unfunded projects
- Lead large collaborations between pharmaceutical industry partners and Geisinger
- Encourage a culture of learning through innovation and research within pharmacy and Geisinger
- Develop implementation and dissemination models for internal Geisinger
- Translate effectiveness research into operational builds, including developing business plans and evaluation methods for new care activities
- Mentor junior researchers

Notable Achievements

- Culture: Conceptualized the model for a pharmacy-based research team at Geisinger and pursued acceptance as a pillar of Enterprise Pharmacy
- Collaborations/Partnerships: Continues to lead established research collaboration efforts between Geisinger and Merck and AstraZeneca and in the process of developing additional research collaborations with several other pharmaceutical partners
- Quality/Service: Continues to lead evaluation and dissemination efforts of ProvenCare® models and ambulatory pharmacy care models of delivery
- Financial Sustainability: Secured internal and external support for research projects, including a \$184,000 Department of Health grant and \$2.2 million Patient-Centered Outcomes Research Institute grant along with overseeing the financial proforma of the CPIO which in FY16 was \$10M

DIRECTOR, AMBULATORY CLINICAL PHARMACY PROGRAMS
July 2012-November 2015 | Geisinger, Danville Pa

Responsibilities

- Oversaw the development and implementation of Ambulatory Clinical Pharmacy programs through managing 54 MTDM/Anticoagulation Clinics, 51 pharmacists and 13 support staff
- Implemented standards, measured performance and took action to promote a customer service-oriented culture
- Evaluated the department's clinical pharmacy programs and made recommendations for the development of new programs based on need and opportunity, specifically in anticoagulation, MTDM and chronic disease management
- Identified factors driving cost trends for anticoagulation/MTDM utilization and contributed to the development of evidence-based, cost containment/cost saving protocols and drug therapies
- Enhanced the ability of the anticoagulation/MTDM clinic staff to provide quality pharmaceutical care by developing, implementing, communicating, and monitoring parameters and encouraging divisional standards for the skills and education necessary to meet system performance standards
- Provided data analysis and program suggestions that facilitated the ability of the system to achieve its goals related to the anticoagulation/MTDM clinics budget management and system performance
- Motivated, energized, directed and supported the staff in the provision of anticoagulation/MTDM

- Assisted the Regional Coordinator, Ambulatory Pharmacy Programs in addressing issues related to the pharmacist's performance

Notable Achievements

- Culture: The system employee engagement survey for the MTDM program was the highest of all system pharmacy and an improvement action plan was not needed
- Collaboration/Partnerships: By utilizing the PA Pharmacist Collaborative Practice Act to its fullest, partnered with primary care physicians to develop, build and expand the MTDM program while increasing access for patient care
- Quality/Service:
 - Planned, developed and deployed minimum competency training/certification processes for MTDM pharmacists
 - The MTDM/Anticoagulation Clinics managed over 18,000 patients on warfarin with >25,000 encounters per month, >2.5%/month growth rate with 70% of INR's within therapeutics range
 - The MTDM Clinics managed over 8,500 patients for chronic disease management such as diabetes, hypertension, hyperlipidemia, oral chemotherapy, anemia, pain, etc.
 - 71% of patients are at recognized therapeutic goal for their disease states and medication adherence rates are >80%
- Financial Sustainability: Developed a fee for service combined with quality/cost avoidance business model for the MTDM program and expansion and since the inception of the program, achieved targets in key performance indicators year after year while deploying clinical resources and services

CLINICAL COORDINATOR OF PHARMACY DISEASE MANAGEMENT SERVICES
2008-2012 | Geisinger, Danville Pa

Responsibilities

- Managed 16 MTDM Clinics, 16 pharmacists and 8 support staff
- Ensured quality metrics and established quality monitors for anticoagulation and evidence-based protocols for MTDM are being followed and met
- Mentored and coached pharmacy personnel on the implementation of optimum standards of pharmaceutical care as an integral part of the health care team

Notable Achievements

- Culture: Engaged the system on all levels to transition the anticoagulation program into a robust MTDM program

- Collaboration/Partnerships: By expanding the utilization of the PA Pharmacist Collaborative Practice Act and partnering with primary care/specialty physicians, developed, built and expanded the anticoagulation program to a disease management program
- Quality/Service:
 - Planned, developed and deployed minimum competency training/certification processes for MTDM pharmacists
 - The MTDM Clinics managed approximately 10,000 patients per month
- Financial Sustainability: Developed a fee for service combined with quality/cost avoidance business model for the MTDM program and expansion and since the inception of the program, achieved targets in key performance indicators year after year while deploying clinical resources and services

CLINICAL COORDINATOR OF PHARMACY ANTICOAGULATION SERVICES
2007-2012 | Geisinger, Danville Pa

Responsibilities

- Managed 22 Anticoagulation Clinics, 23 pharmacists and 8 support staff
- Led pharmaceutical care, cost containment/cost savings initiatives and ensured appropriate evidence-based medication guidelines are implemented and followed
- Identified and took advantage of opportunities to improve the health and wellness of the patients served by Geisinger in conjunction with the overall goals and objectives of the system

Notable Achievements

- Culture: During the development of the strategic plan to transition the anticoagulation clinics into MTDM clinics, identified the cultural shift needed between pharmacy and primary care clinicians to execute the MTDM system plan
- Collaboration/Partnerships: By expanding the utilization of the PA Pharmacist Collaborative Practice Act and partnering with non-Geisinger primary care/specialty physicians, developed, built and expanded the anticoagulation program for GHP patients who were not being seen within the system; truly a model of population health
- Quality/Service: The Anticoagulation Clinics managed over 10,500 active patients on warfarin with >16,000 encounter per month, >1% per month growth rate with 70% of INR's within therapeutic range and 220-350 patients treated with low molecular weight heparin per month

CLINICAL PHARMACIST - ANTICOAGULATION CLINIC
1997-2007 | Geisinger, Danville Pa

Responsibilities

- Received and interpreted physicians' referral orders and clarified or corrected orders with the physician
- Reviewed patient medication profiles to guard against drug sensitivities, contraindications, duplications, and major drug interactions
- Consulted and advised members of the medical staff on matters relating to specific drug therapy problems and monitors and act on patient laboratory results
- Provided in-depth drug information and other informational materials to members of the medical, nursing and other healthcare professionals
- Provided patient discharge medication consultations based on department standards
- Calculated drug dosages based on pharmacokinetic parameters
- Provided patient with appropriate educational materials and information in order help them understand and participate in their care

Notable Achievements

- Conceptualized pharmacist-driven outpatient management of anticoagulation
- Initiated single anticoagulation service within GMC in 1997 with 1 FTE managing ~340 active patients
- The Geisinger Medical Center Anticoagulation Clinic managed over 3400 active patients on warfarin with patients being primarily referred from internal medicine, cardiology, hematology, oncology, orthopedics, and family practice
- Warfarin monitoring and education provided either in the clinic or via telephone conversation, averaging 200 patients a day
- Provided training and education for low molecular weight heparin patients, averaging 55 patients a month, for either bridging therapy or outpatient deep vein thrombosis and pulmonary embolism treatment

CLINICAL PHARMACIST - INPATIENT PHARMACY
1996-1997 | Geisinger, Danville Pa

Responsibilities

- Covered central inpatient pharmacy, operating room satellite, Med/Surg, Cardiac and Intensive Care floors
- Provided patient education
- Provided drug information to physicians and nurses

- Compounded oral, parenteral and topical medications
- Reviewed patient medication profiles

RETAIL PHARMACIST

1998-2006| Bloomsburg Hospital, Bloomsburg Pa

RETAIL PHARMACIST

1996-2009| Medicine Shoppe, Bloomsburg Pa

PHARMACY TECHNICIAN

1994-1996| Geisinger, Danville Pa

PROFESSIONAL AWARDS

2020 FASHP-Fellow American Society of Health System Pharmacy

2016 ASHP Foundation and Cardinal Health Foundation Finalist Award for Excellence in Medication Safety for Medication Therapy Disease Management’s Chronic Pain Management

2016 PSHP Innovative and Collaborative Practice Award for Geisinger Health System Medication Therapy Disease Management (MTDM) Program

2016 ASHP Board of Director’s Award of Excellence for Geisinger Health System Medication Therapy Disease Management (MTDM) Program for consistently demonstrating the value pharmacists play in improving care and reducing costs

2015 Next-Generation Pharmacist of the year Award by Parata and Pharmacy Times

2015 Next-Generation Health-System Pharmacist of the year Award by Parata and Pharmacy Times

EDUCATION

MBA Healthcare Management - February 2019 - Present
Western Governors University

E. Allen Deaver Leadership Program-July 2017-2018
Geisinger/University of Scranton

Partners in Leadership: Leadership Development Curriculum-March 2015
Geisinger/University of Scranton

Antithrombosis Management Preceptorship – February 2006
University of Illinois at Chicago College of Pharmacy

Bachelor of Pharmacy – May 1996
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia

Philadelphia, Pennsylvania

Bachelor of Science in Biology-May 1992

Minor Chemistry

Millersville University

Millersville, Pennsylvania

PROFESSIONAL LICENSURE

Pennsylvania (Pharmacist RP-042952-L) – 1996

Pilots License (FAA 3099470) - 1994

PROFESSIONAL SOCIETY MEMBERSHIPS

American Pharmacists Association

American Society of Health-System Pharmacists

North Central Chapter of Pennsylvania Society of Health-System Pharmacists

President January 2001 to May 2003

President-Elect May 2000 to January 2001

Treasurer January 1998 to 2000

EXTERNAL COMMITTEE MEMBERSHIPS

2019-Present: ASHP Opioid Task Force

2019-Present: ASHP Practice Advancement Initiative 2030 Advisory Council

2018-Present: Premier Generic Drug Initiative Advisory Council

2018-Present: Wilkes University, Nesbitt School of Pharmacy, Dean's Advisory Council

2016-2019: PSHP Legislative Committee

2016-2019: Pfizer- System of Care Grant Oversight Committee

1997-Present: Drug Information Newsletter-representative/contributing member

GEISINGER COMMITTEE MEMBERSHIPS

2019: JPMorgan Healthcare Advisory Council – panel member

2019-Present: Geisinger Education Council

2017-Present: Innovation Council

2017-Present: Care Redesign Steering Committee

2017-Present: ProvenCare[®] Steering Committee

2017-Present: Population Health Leadership

2017-Present: Pharmacogenomics Advisory Committee

2017-Present: Return of Results Clinical Oversight Committee

2017-Present: High Impact Chronic Conditions Steering Committee

2017-Present: Primary Care Quality Shared Governance Committee

2017-2019: CEO – Innovation Workgroup Committee

2017-2019: Health Transformation Alliance Expert Clinical Advisory Panel
 2017-2019: Access Steering Committee
 2016-Present: Patient Education Steering Committee
 2016-Present: Hem/Onc Steering Committee
 2016-Present: Quality Improvement Committee
 2016-Present: Geisinger Population Health Steering Committee
 2016-Present: Geisinger-AstraZeneca Collaboration Steering Committee
 2016-2019: Springboard Health
 2015-2019: Geisinger-Merck Collaboration Steering Committee
 2014-2016: Geisinger Health System: Pride Medication Reconciliation Steering Committee member
 2014-2016: Geisinger Health System: Merck; Patient Validated Medication Adherence System, Leader
 2013-2016: Geisinger Health System Pride Pain Steering Committee Administrative Lead and Ambulatory Team Lead
 2013-Present: Geisinger Health System Enterprise Pharmacy Leadership member
 2013-2019: Geisinger Health System Community Practice Leadership member
 2013-2019: Geisinger Health System xG Health Solutions program member
 2012-2016: Geisinger Health System Subspecialty Care/Medical Home panel member
 2012-2016: Geisinger Health System Skilled Nursing Facility Program panel member.
 2012-2014: Geisinger Health System Modules of Care panel member
 2011-2016: Geisinger ADA Program Steering Committee panel member.
 2011-2015: Geisinger Health System Anticoagulation Steering Committee-Chair
 2010-2016: Geisinger Health System Medical Mining-Consultant
 2009-2012: Geisinger Health System Orthopedic Care Map-Performance Improvement Committee
 2008-2009: National Patient Safety Goal 3E Geisinger Medical Center panel member
 2009: Anti-Coagulation Clinic Consortium) National Survey/AC Forum-survey development/panel member
 2008-2016: Medical Mining-Consultant/Panel Member
 2008: Family Practice Atrial Fibrillation Protocol-Development/Panel Member
 2006-2014: Health and Technology Vector Inc., clinical liaison
 2005-2015: Transitions of Care, Improvement Committee
 2005-2015: Proven Care, Risk Assessment Committee
 2004-2011: Anticoagulation Steering Committee-representative/contributing member

PRESENTATIONS

1. 2020: Integrated Care Delivery Response to COVID-19 in Enterprise Pharmacy at Geisinger, webinar panelist for ASHP Advantage ADV (elearning@ashp.org)
2. 2019: Health System Strategy to Address the Opioid Crises: Premier, Nashville, TN

3. 2019: Battling the Opioid Epidemic Together: Collaborating with an Innovative Integrated Health Services Organization to Reduce Opioid Overutilization; MedImpact, Carlsbad, CA
4. 2018: Geisinger's Approach to the Increasing Opioid Epidemic; CHIME Webinar, April 25, 2018
5. 2018: Geisinger Response to Opioid Epidemic; PSHP, Harrisburg, PA
6. 2018: Geisinger Response to Opioid Epidemic; CNIO & Population Health Meeting, Dallas, TX
7. 2017: The Opioid Epidemic: Origin, Issues, and Action; Cardinal Health Foundation at ASHP Midyear Conference, Orlando, FL
8. 2017: Best Practices in ePA Functionality Across an Integrated Delivery Network; CBI Electronic Benefit Verification and Prior Authorization Summit, San Francisco, CA
9. 2017: Diagnosis to Dispensing to Care: Insights from a Regional IDN to Specialty Disease Management; CarePath Approach; Asembia Specialty Pharmacy Summit, Las Vegas, NV
10. 2016: How to Decrease Cost while Improving Quality and Safety: Medication Therapy Disease Management Program; Health Connect Partners Spring Hospital Pharmacy Conference, Atlanta, GA
11. 2016: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; Maryland Society of Health System Pharmacists, Hanover, MD
12. 2016: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; Philadelphia College of Pharmacy, Philadelphia, PA
13. 2016: The Virtual Clinical Pharmacy: Medication Therapy Disease Management Program; xG Health Consortium, Baltimore, MD
14. 2016: Opioid & Controlled Substance Prescribing; PA Department of Health, Lewistown, PA
15. 2015: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; Pennsylvania Society of Health System Pharmacists, Lancaster, PA
16. 2015: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; Adirondack Health System, Adirondack, NY
17. 2014: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; Eastern Maine Health System, Bar Harbor, ME
18. 2015: GHS Medication Therapy Disease Management (MTDM) Program: Endless Opportunities; American Journal Managed Care Webcast
19. 2015: Role of Pharmacists on Disease Management; ASHP Summer Meeting and Exhibition, Denver, CO

20. 2015: GHS Medication Therapy Disease Management (MTDM) Program Update; Premier Annual Breakthrough Conference and Exhibition, National Harbor, MD
21. 2015: GHS Medication Therapy Disease Management (MTDM) Program Update; Health Connect Partners Spring Hospital Pharmacy Conference, Orlando, FL
22. 2015: “Michael Evans, RPh. Describes Geisinger’s Approach to MTM Programs” by AJMctv on YouTube <https://www.youtube.com/watch?v=UFBv2BQR2s8>
23. 2015: “Michael Evans, RPh. Discuss Geisinger’s Role in the IDN/ACO Marketplace” by AJMctv on YouTube https://www.youtube.com/watch?v=t55shXoj_mE
24. 2014: How to Decrease Cost while Improving Quality and Safety: Medication Therapy Disease Management Program; ASHP Midyear Clinical Meeting and Exhibition, Anaheim, CA
25. 2014: How to Decrease Cost while Improving Quality and Safety: Medication Therapy Disease Management Program; ASHP Summer Meeting and Exhibition, Las Vegas, NV
26. Implementing a Pharmacist Run Oral Chemotherapy Medication Therapy Management Clinic in an Outpatient Hematology/Oncology Clinic; National Cancer Institute, Baltimore, MD
27. 2013: Risk of Recurrent Venous Thromboembolism Among Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Warfarin; Journal of Managed Care September 2013
28. 2013: Coagulation Management Programs: Priming of Care Device Management; Keystone Point of Care Coagulation, Gettysburg Hospital, Gettysburg, PA

PEER REVIEWED ARTICLES

1. Jones LK, Graham J, Gionfriddo M R, **Evans MA**, Ladd IG, Gregor C. (2019). Understanding the medication prior authorization process: a case study of patients and clinical staff from a large rural integrated health delivery system. *American Journal of Health-System Pharmacy*, 76(7),453–459, <https://doi.org/10.1093/ajhp/zxy083>
2. Wright E, **Evans MA**, Kern M, Gionfriddo M. How Geisinger Health System Reduced Opioid Prescriptions. *Harvard Business Review*. 2018.[ePub ahead of print <https://hbr.org/2018/11/how-geisinger-health-system-reduced-opioid-prescriptions>]
3. Sandeep K, Gaines S, Lee T, **Evans MA**. (2018). Enhanced Cure Rates for HCV: Geisinger’s Approach. *NEJM Catalyst*, <https://catalyst.nejm.pdf>

4. Jones LK, Pulk R, Gionfriddo M R, **Evans MA**, Parry D. (2018). Utilizing big data to provide better health at lower cost. *American Journal of Health-System Pharmacy*, 75(7), 427-435.
5. Gionfriddo MR, **Evans MA**, et al. ProvenCare-Psoriasis: A disease management model to optimize care. *Dermatology Online Journal*. 2018. [accepted for mid-March]
6. Slabodkin G, **Evans MA**, et al. Geisinger slashes prescriptions for opioids in half using provider dashboard. *Health Data Management*. 2017, <https://www.healthdatamanagement.com/news/geisinger-slashes-opioid-prescriptions-in-half-using-dashboard-for-docs>
7. Williams BA, **Evans MA**, Honushefsky AM, Berger PB. Clinical Prediction Model for Time in Therapeutic Range while on Warfarin in Newly Diagnosed Atrial Fibrillation. *Journal of the American Heart Association*. 2017. [ePub ahead of print, DOI: 10.1161/JAHA.117.006669].
8. Deitelzweig SB, **Evans M**, Trocio J, Gupta K, Lingohr-Smith M, Menges B, Lin J. Impact of warfarin persistence on health-care utilization and costs among patients with atrial fibrillation managed in anticoagulation clinics in the United States. *Clin Appl Thromb Hemost*. 2017. [ePub ahead of print, DOI: 10.1177/1076029616685427]
9. Jones LK, Greskovic G, Grassi DM, Graham J, Sun H, Gionfriddo MR, Murray MF, Manickam K, Nathanson D, Wright EA, **Evans MA**. Medication Therapy Disease Management: Geisinger's Approach to Population Health Management. *AJHP*. 2017; 74:1422-35.
10. Graham J, Sanchez RJ, Saseen J, Mallya UG, Panaccio MP, **Evans MA**. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. *Journal of Clinical Lipidology*. 2017; 11:70-79.
11. Deitelzweig S, **Evans M**, Hillson E, et al. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. *Curr Med Res Opin*. 2016;32(1):87-94.
12. https://geisinger.sharepoint.com/sites/CPIOAdmin/Lists/AbstractsPublicationsPresentations/Attachments/3/2016_Evans_SocialInnovationsJournal_PharmacistsAsPotentialOptionToCurrentDoctorShortage.xps
13. Nordstrom BL, **Evans MA**, Murphy BR, Nutescu EA, Schein JR, Bookhart BK. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. *Curr Med Res Opin*. 2015;31(3):439-447.
14. Dullabh PM, Sondheimer NK, Katsh E, **Evans MA**. How patients can improve the accuracy of their medical records. *eGEMS (Generating Evidence & Methods to improve patient outcomes)*. 2014;2(3):10.

15. Brummel A, Lustig A, Westrich K, **Evans MA**, Plank GS, Penso J, Dubois RW. Best practices: Improving patient outcomes and costs in an ACO through comprehensive medication therapy management. *J Manag Care Spec Pharm*. 2014;20(12):1152-1158.

NON-PEER REVIEWED ARTICLES

1. **Evans M**. Pharmacists as potential option to current doctor shortage. *Social Innovations Journal*. 2016 October 18;28.
<http://www.socialinnovationsjournal.org/editions/issue-28-fall-2016/75-disruptive-innovations/2135-pharmacists-as-potential-option-to-current-doctor-shortage>

BOOK CHAPTERS

1. Steele G, Feinberg D, **Evans M**, et al. Chapter 9 of ProvenCare: How to Deliver Value-Based Healthcare in the Geisinger Way; McGraw-Hill Education; 1 edition (November 3, 2017)

PUBLISHED ABSTRACTS

1. Jones LK, Pulk R, Gionfriddo MR, **Evans MA**, Parry D. Utilizing big data to provide better health at lower cost. *American Journal Health System Pharmacy*. 2018; 75:427-435 doi:10.2146/ajhp170350
2. Pulk R, Jones L, Chronowski J, Pride H, Wright E, **Evans M**. Geisinger's Use of Clinical CarePaths: Impact of a Psoriasis CarePath on Process, Clinical, and Economic Outcomes. *Journal of Patient-Centered Research and Reviews*. 2017;14(3):98.
3. Jones LK, Wright EA, Hartzel DN, Lindbuchler D, Leader JB, Kirchner HL, Overton J, Reid JG, **Evans MA**, Dewey FE, Murray MF. Baseline undertreatment of adults with newly diagnosed familial hypercholesterolemia by genomic sequencing*. *Journal of Clinical Lipidology*. 2016;10(3):692-693.
4. Jones LK, Wright EA, **Evans M**, Williams MS, Murray MF. An innovative patient-centered, multidisciplinary approach for the delivery of genomic sequencing results and pharmacist-led lipid management to patients with familial hypercholesterolemia. *Journal of Patient-Centered Research and Reviews*. 2016; 3:194.
5. Roumia M, Berger P, **Evans M**, Steinhubl S. DO STATINS INCREASE BLEEDING RISK IN ANTICOAGULATED INDIVIDUALS? *Journal of the American College of Cardiology*. 2015;65(10S): A1440.

6. Deitelzweig S, **Evans M**, Hillson E, et al. DOES WARFARIN TIME-IN-THERAPEUTIC RANGE AFFECT HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE U.S.? *Journal of the American College of Cardiology*. 2015;65(10): A1515.
7. Saeed B, Wright E, **Evans M**, Lewis M, Steinhubl S. Prevalence of Statin Intolerance in a High-Risk Cohort and Management Strategies in Contemporary Cardiology. *Clin Med Res*. 2013 Sep;11(3):136.
8. Harrison HH, **Evans MA**, Amarose EM, et al. Comparison of prothrombin time-international normalized ratio values derived from point-of-care devices versus coagulation instrument results in a multisite, anticoagulation clinic setting. *Arch Pathol Lab Med*. 2011;135(9):1102-1230.

POSTERS

1. Sundaresan AS, Sees AC, Greskovic GA, **Evans MA**, Brady JP, Gerrity GJ, Beeler CL, Rohrer GR, Simonelli PF, Perez CR. Quality Improvement for Asthmatics: Reducing Emergency Department Visits for High-risk Asthmatics through Clinical Informatics and Clinical Pharmacist Management Program. 2017 American Academy of Pediatrics National Conference. Chicago, IL, September 2017
2. Jones LK, Wright EA, Hartzel DN, Lindbuchler D, Leader JB, Kirchner HL, Overton J, Reid JG, **Evans MA**, Dewey FE, Murray MF. Baseline Undertreatment of Adults with Newly Diagnosed Familial Hypercholesterolemia by Genomic Sequencing. Oral presentation, 2016 National Lipid Association Scientific Sessions. New Orleans, LA, May 2016.
3. Jones L, Graham J Maeng D, **Evans M**, Harris R, Wright E. Oral Antidiabetic Medication Adherence and Glycemic Control Associated with Fewer Hospitalizations and Emergency Department Visits. 22nd Annual Health Care Systems Research Network Meeting. Atlanta, GA April 14-16, 2016.
4. Jones L, Wright E, **Evans M**, Williams M, Murray M. An Innovative Patient-centered, Multidisciplinary Approach for the Delivery of Genomic Sequencing Results and Pharmacist-led Lipid Management to Patients with Familial Hypercholesterolemia. 22nd Annual Health Care Systems Research Network Meeting. Atlanta, GA, April 14-16, 2016.
5. Deitelzweig S, **Evans M**, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Lin J. A Conservative Approach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in an Integrated Healthcare Delivery System Setting in the U.S. ISPOR 20th Annual International Meeting. Philadelphia, PA. May 16-20, 2015.

6. Roumia M, Berger P, **Evans M**, Steinhubl S. DO STATINS INCREASE BLEEDING RISK IN ANTICOAGULATED INDIVIDUALS? American College of Cardiology Scientific Session 2015. San Diego, CA. March 14-16, 2016.
7. Deitelzweig S, **Evans M**, Trocio J, Gupta K, Lingohr-Smith M, Menges B, Lin J. Impact of Warfarin Adherence Status on Healthcare Costs Among Patients with Nonvalvular Atrial Fibrillation; AMCP Managed Care & Specialty Pharmacy Annual Meeting (Poster No. I08); San Francisco, CA; April 21, 2016.
8. Harrison HH, **Evans MA**, Amarose EM, Greskovic G, Rencavage KS, Webster LK, Forsythe MF, Dorion RP, Fitt WM, Jones JB. Comparison of Prothrombin Time–International Normalized Ratio Values Derived From Point-of-Care Devices Versus Coagulation Instrument Results in a Multisite, Anticoagulation Clinic Setting (Poster No. 74). College of American Pathologists 2011 Annual Meeting. Grapevine, TX, September 11-14, 2011.
9. 2011-2012: Demonstrating the Effectiveness of Online Patient Feedback in Improving the Data Quality of Medical Records, presented to ONC September 2011

JOURNAL REVIEWER

1. 2015: Journal of Managed Care & Specialty Pharmacy Reviewer for the manuscript entitled "Estimating the Economic Impact of Adding Panobinostat to a US Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model"
2. 2015: Journal of Managed Care & Specialty Pharmacy Reviewer for the manuscript entitled "Retrospective Study of Real-World Axitinib Use in the United States through Use of Linked HIPAA-Compliant Data Sets"

ACKNOWLEDGEMENTS

1. 2019: Rising prescription drug prices leave seniors struggling by Katelyn Hibbard and Lauren Rude, Williamsport Sun Gazette, October 13, 2019
<http://www.sungazette.com/news/top-news/2019/10/rising-prescription-drug-prices-leave-seniors-struggling/>
2. 2019: Highmark, Geisinger address steps to combat opioid abuse by Eric Scicchitano, Danville News, May 14, 2019
https://www.dailyitem.com/the_danville_news/news/highmark-geisinger-address-steps-to-combat-opioid-abuse/article_8f750293-bb20-5145-a1c0-becb675dc15b.html
3. 2018: When the Price of Medications Keeps Patients from Taking Them by Timothy Kelley, Managed Care Magazine, June 3, 2018

<https://www.managedcaremag.com/archives/2018/6/when-cost-medications-keeps-patients-taking-them> or
[http://editiondigital.net/publication/?i=499913#{"issue_id":499913,"page":0}](http://editiondigital.net/publication/?i=499913#{)

4. 2018: Health Care Advisory Board Opioid Resources Overview by The Advisory Board Company
5. 2018: How Geisinger is Responding to the Opioid Crisis and Cutting ED Visits in the Process by The Advisory Board Company
6. 2018: How a PA health system reduced opioid prescriptions by more than half by Alan Yu, WHYY, April 9, 2018
7. 2018: Four pain management programs curbing the opioid epidemic by Tracey Walker, Managed Healthcare® Executive, January 23, 2018
8. 2017: Geisinger slashes prescriptions for opioids in half using provider dashboard by Greg Slabodkin, Health Data Management, Dec 11, 2017 7:12am EST.
9. 2017: Special Report: Confronting the Opioid Epidemic by The Advisory Board Company
10. 2016: A Prescription for Peace of Mind Geisinger Magazine by Susan Worley Spring 2016 pgs 36-39
11. 2016: Urgent Heart-Failure Clinics as Hubs for Fully Integrated Care, published in NEJM Catalyst, March 23, 2016.
12. 2013: Innovations in Medication Therapy Management; Effective Practice for Diabetes Care and Other Chronic Conditions; AHIP, December 2013 pgs.27-31.
13. 2013: The Strategy That Will Fix Health Care; Harvard Business Review, October 2013
14. 2013: Evans M. Geisinger Health System: Providing a one-stop shop for medication management. Innovations in Medication Therapy: Effective Practices for Diabetes Care and Other Chronic Conditions, 26-27.
15. 2012: Role of Pharmaceutical in Value-Based Healthcare: A Framework for Success; published in Journal of Managed Care July 2012

BIOSKETCH RESEARCH ACTIVITIES

1. 2017: Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Non-Cancer Pain in Primary Care; Patient-Centered Outcomes Research Institute, August 2017
2. 2016: Geisinger-Intarcia Diabetes Study: Assessment of Medication Adherence, Glycemic Control and Healthcare Utilization among Patients with Type 2 Diabetes Mellitus, January 2016
3. 2015: Retrospective Analysis of the Geisinger Health System Anticoagulation Clinic to Develop a Method to More Rapidly Identify Patients with Atrial

- Fibrillation in Whom Warfarin Levels Will Be Difficult to Maintain in Therapeutic Range, October 2015
4. 2014: Systems of Care for Patients with Chronic Pain. Geisinger Health Plan Quality Fund Proposal, December 2014
 5. 2014: Expanding Applied Clinical Analytics to Improve Quality and Safety at the Point of Care. Geisinger Health Plan/Geisinger Clinic Quality Fund Proposal, December 2014
 6. 2014: Optimizing High-Cost Biologic Treatments for Patients with Psoriasis and Multiple Sclerosis. December 2014
 7. 2014: Reducing Suffering: Toxicity, Comorbidity and Value-Based Care for High-Risk Cancer Patients. Geisinger Health Plan Quality Fund Proposal, December 2014
 8. 2014: Systems of Care for Patients-Families with Dementia. Geisinger Health Plan/Geisinger Clinic Quality Fund *Proposal, December 2014*
 9. 2014: Impact of the Medication Therapy Management (MTM) Pain Pharmacist in the Management of Pain Clinic Patients with Chronic, Non-Cancer Pain, October 2014
 10. 2014: Protocolized Early Identification and Action in CKD: A Pilot Pragmatic Trial”
 11. 2013: Patient Validated Medication Adherence System; Executive Team
 12. 2013: Evaluating mobile technology in the management of diabetes, hypertension and hyperlipidemia; Co-Investigator
 13. 2013: An examination of the bleeding risk associated with the concomitant use of statins and warfarin; Primary Investigator
 14. 2010-2015: Recognized Therapeutic Outcome for Hypertension, Diabetes, and Dyslipidemia in Pharmacist-managed Medication Therapy Management (MTM) Clinics; Primary Investigator
 15. 2010-2017: MyGeisinger Medication Reconciliation with patient entered information, Primary Investigator
 16. 2007-2010: ROCKET AF Study Investigator
 17. 2009-2013: ENGAGE –AF Study Investigator
 18. 2009-2016: Medication ADHERENCE GHP trial
 19. 2008: Side-by-Side “Lean” Process Mapping of Fingerstick I-STAT PT/INR versus venipuncture Stago PT/INR

EXTRAMURAL PROFESSIONAL ACTIVITIES

2018-Present: Wilkes University, Nesbitt School of Pharmacy, Dean's Advisory Council

2017-Present: PSHP Legislative Committee Member

2014-2016: Merck US Diabetes Board Member
2014-2015: Daiichi Sankyo US Board Anticoagulation
2013-2015: Fischer Scientific Consultant/Speaker
2012-2015: Roche Pharmaceuticals Consultant/Speaker Community
2011-2012: Boehringer Ingelheim Speaker Community
2011-2017: Janssen Pharmaceuticals Speaker Community
2009-2016: Consultant-MedMining
2008-2010: Lovenox Speaker Bureau, Aventis Pharmaceuticals